




Company Overview


Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs.

Defining Next-Generation Allogeneic CAR T Development



Pursuing a Differentiated Strategy for CAR Ts

All-in-One vector approach
Proprietary allogeneic technologies
shRNA – short hairpin RNA
shARC – shRNA Armored CAR franchise
TIM – TCR Inhibitory Molecule




shRNA-Powered Allogeneic Technology

Non-gene edited shRNA platform offers dynamic technology for the potential development of allogeneic CAR Ts

Able to multiplex by simultaneously knocking down multiple gene targets of interest

Currently being evaluated in multiple clinical trials and discovery programs



Robust Intellectual Property Estate

Twelve foundational U.S. patents associated with allogeneic CAR T for the treatment of cancer

Strong IP for NKG2D receptor-based cell therapies

A Differentiated Pipeline of Next Generation CAR T Candidates

Allogeneic

| | TARGET | INDICATION | PRECLINICAL | PHASE 1 | PHASE 2 | NEXT MILESTONES |
|--------------------|--------|------------|-------------|---------|---------|---|
| CYAD-211 | BCMA | r/r MM | | | | <ul style="list-style-type: none"> Additional clinical data expected H2:2022 |
| CYAD-101 | NKG2DL | mCRC | | | | <ul style="list-style-type: none"> Update on CYAD-101-002 trial* |
| DISCOVERY PROGRAMS | | | | | | |

Autologous

| | TARGET | INDICATION | PRECLINICAL | PHASE 1 | PHASE 2 | NEXT MILESTONES |
|---------|--------|---------------|-------------|---------|---------|---|
| CYAD-02 | NKG2DL | r/r AML / MDS | | | | <ul style="list-style-type: none"> Potential partnership opportunity |

Company Financial Overview



Listed on:

Euronext & Nasdaq
CYAD

Market Capitalization:

~ €33,56 M

Cash Balance*:

€ 20.5 million

*(all figures reported as of March 31, 2022)

Leadership



Filippo Petti
CEO / CFO



Charles Morris
CMO



David Gilham
CSO



Philippe Dechamps
CLO



Frédéric Lehmann
VP Clinical Dev.
& Med. Affairs



Philippe Nobels
VP Human Resources

Upcoming Milestones

❑ CYAD-211 in r/r MM

Enrollment in the cohorts evaluating enhanced lymphodepletion is ongoing in the CYAD-211 IMMUNICY-1 trial and additional data from the trial are expected in the second half of 2022

❑ shARC Franchise

Exploration continues for allogeneic NKG2D receptor CAR T candidates currently in the discovery stage that leverage the shARC platform.

Partnerships

Since its incorporation, Celyad Oncology has built strong partnerships with key international academic institutions and strategic organizations in order to maximize the therapeutic potential of its product candidates and intellectual property.

Our Partners:

- Celdara Medical
- Dartmouth College
- Horizon Discovery
- MSD
- Novartis
- Walloon Region of Belgium



Locations

Headquarters:

Axis Business Park
Rue Edouard Belin 2,
1450 Mont-Saint-Guibert
Belgium

World Financial District
60 Broad Street | Suite 3502
New York, NY 10004
USA



Contacts

+32 (0) 10 39 41 00
+1 (857) 990-6900

info@celyad.com